Bausch + Lomb Corporation

TSX:BLCO Stock Report

Market Cap: CA$8.2b

Bausch + Lomb Valuation

Is BLCO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLCO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CA$104.03
Fair Value
77.5% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: BLCO (CA$23.43) is trading below our estimate of fair value (CA$104.03)

Significantly Below Fair Value: BLCO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLCO?

Key metric: As BLCO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BLCO. This is calculated by dividing BLCO's market cap by their current revenue.
What is BLCO's PS Ratio?
PS Ratio1.2x
SalesUS$4.68b
Market CapUS$5.78b

Price to Sales Ratio vs Peers

How does BLCO's PS Ratio compare to its peers?

The above table shows the PS ratio for BLCO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
CSH.UN Chartwell Retirement Residences
5.5x12.0%CA$4.5b
AND Andlauer Healthcare Group
2.7x4.8%CA$1.8b
MMSI Merit Medical Systems
4.8x7.2%US$6.3b
YPSN Ypsomed Holding
8.2x15.9%CHF 5.1b
BLCO Bausch + Lomb
1.2x4.7%CA$5.8b

Price-To-Sales vs Peers: BLCO is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does BLCO's PS Ratio compare vs other companies in the CA Medical Equipment Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.9x7.9%
BLCO Bausch + Lomb
 1.2x4.7%US$5.78b
HTL Hamilton Thorne
3.2x9.1%US$246.63m
NSCI Nanalysis Scientific
0.8x6.1%US$23.94m
BLCO 1.2xIndustry Avg. 3.9xNo. of Companies8PS020406080100+
9 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.9x12.5%
BLCO Bausch + Lomb
 1.2x58.5%US$5.78b
No more companies

Price-To-Sales vs Industry: BLCO is good value based on its Price-To-Sales Ratio (1.2x) compared to the North American Medical Equipment industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is BLCO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLCO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio4.9x

Price-To-Sales vs Fair Ratio: BLCO is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (4.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLCO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$23.43
CA$29.29
+25.0%
11.4%CA$35.43CA$25.51n/a15
Feb ’26CA$25.12
CA$30.04
+19.6%
11.4%CA$36.34CA$26.17n/a15
Jan ’26CA$25.96
CA$29.97
+15.4%
13.4%CA$36.99CA$25.61n/a15
Dec ’25CA$27.80
CA$29.90
+7.6%
13.4%CA$36.29CA$25.12n/a14
Nov ’25CA$28.62
CA$29.90
+4.5%
13.4%CA$36.29CA$25.12n/a14
Oct ’25CA$25.80
CA$27.25
+5.6%
10.7%CA$33.73CA$24.28n/a15
Sep ’25CA$22.14
CA$27.36
+23.6%
12.3%CA$34.66CA$22.18n/a15
Aug ’25CA$23.53
CA$27.47
+16.7%
12.3%CA$34.68CA$22.20n/a15
Jul ’25CA$19.80
CA$25.58
+29.2%
17.3%CA$34.17CA$19.13n/a14
Jun ’25CA$21.06
CA$25.58
+21.4%
17.3%CA$34.17CA$19.13n/a14
May ’25CA$18.90
CA$26.49
+40.2%
19.2%CA$35.77CA$19.26n/a15
Apr ’25CA$23.24
CA$26.86
+15.6%
16.1%CA$35.12CA$21.61n/a15
Mar ’25CA$22.35
CA$26.86
+20.2%
16.1%CA$35.12CA$21.61n/a15
Feb ’25CA$18.84
CA$26.30
+39.6%
15.7%CA$34.96CA$21.51CA$25.1214
Jan ’25CA$22.67
CA$26.33
+16.1%
15.7%CA$34.76CA$21.39CA$25.9613
Dec ’24CA$20.88
CA$27.72
+32.7%
13.9%CA$35.30CA$23.08CA$27.8012
Nov ’24CA$22.91
CA$28.17
+22.9%
11.3%CA$36.04CA$24.95CA$28.6211
Oct ’24CA$23.08
CA$28.48
+23.4%
10.3%CA$34.76CA$24.07CA$25.8010
Sep ’24CA$24.41
CA$28.48
+16.7%
10.3%CA$34.76CA$24.07CA$22.1410
Aug ’24CA$25.76
CA$27.89
+8.3%
11.6%CA$34.24CA$22.39CA$23.5313
Jul ’24CA$26.52
CA$27.45
+3.5%
11.7%CA$34.44CA$22.52CA$19.8013
Jun ’24CA$24.50
CA$27.95
+14.1%
11.0%CA$33.77CA$22.96CA$21.0613
May ’24CA$23.63
CA$27.91
+18.1%
11.8%CA$33.85CA$23.02CA$18.9013
Apr ’24CA$23.48
CA$29.06
+23.8%
15.7%CA$40.82CA$23.13CA$23.2414
Mar ’24CA$24.33
CA$29.06
+19.4%
15.7%CA$40.82CA$23.13CA$22.3514
Feb ’24CA$23.14
CA$27.06
+16.9%
19.3%CA$40.45CA$20.22CA$18.8414
Analyst Price Target
Consensus Narrative from 15 Analysts
CA$29.50
Fair Value
20.6% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 16:10
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bausch + Lomb Corporation is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Matt MiksicBarclays
Craig BijouBofA Global Research